2025 North America Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 North America Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in ALS treatment in North America include Biogen, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Therapeutics, and Amylyx Pharmaceuticals. Biogen is a key leader due to its extensive neurodegenerative disease research and approved ALS therapies. Mitsubishi Tanabe Pharma, part of Mitsubishi Chemical Group, is notable for its global ALS treatment portfolio, including edaravone. BrainStorm Cell Therapeutics focuses on stem cell therapies aimed at slowing disease progression. Amylyx Pharmaceuticals is recognized for its novel drug development and recent approvals targeting ALS symptom management.
These companies benefit from North America’s robust healthcare infrastructure, strong clinical trial support, favorable reimbursement policies, and growing patient awareness, which drives innovation and accessibility. Their active engagement includes development of gene therapies, antisense oligonucleotides (ASOs), and neuroprotective drugs aiming to address inflammation, oxidative stress, and motor neuron protection. For example, investigational gene therapies like Klotho Neurosciences’ KLTO-202 aim to protect nerve cells, while stem cell and oral treatments remain important in clinical and commercial strategies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in ALS treatment in North America include Biogen, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Therapeutics, and Amylyx Pharmaceuticals. Biogen is a key leader due to its extensive neurodegenerative disease research and approved ALS therapies. Mitsubishi Tanabe Pharma, part of Mitsubishi Chemical Group, is notable for its global ALS treatment portfolio, including edaravone. BrainStorm Cell Therapeutics focuses on stem cell therapies aimed at slowing disease progression. Amylyx Pharmaceuticals is recognized for its novel drug development and recent approvals targeting ALS symptom management.
These companies benefit from North America’s robust healthcare infrastructure, strong clinical trial support, favorable reimbursement policies, and growing patient awareness, which drives innovation and accessibility. Their active engagement includes development of gene therapies, antisense oligonucleotides (ASOs), and neuroprotective drugs aiming to address inflammation, oxidative stress, and motor neuron protection. For example, investigational gene therapies like Klotho Neurosciences’ KLTO-202 aim to protect nerve cells, while stem cell and oral treatments remain important in clinical and commercial strategies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
